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BalanceChorea may contribute to balance problems and walking difﬁculties that lead to higher fall rates in individuals
with Huntington's disease (HD). Few studies have examined the effects of tetrabenazine (TBZ), an anti-choreic
drug, on function and mobility in HD. The purpose of this study was to compare: 1) gait measures in forward
walking, 2) balance and mobility measures, and 3) hand and forearm function measures on and off TBZ. We hy-
pothesized that use of TBZwould improve gait, transfers and hand and forearm function. Eleven individuals with
HD on stable doses of TBZ were evaluated while off medication and again following resumption of medication.
Signiﬁcant improvements were found on the Uniﬁed Huntington's Disease Rating Scale (UHDRS) motor scores,
Tinetti Mobility Test (TMT) total (t = 4.20, p = 0.002) and balance subscale (t =−4.61, p = 0.001) scores,
and the Five Times Sit-to-Stand test (5TSST, t= 3.20, p= .009) when on-TBZ compared to off-TBZ. Spatiotem-
poral gait measures, the Six Condition Romberg test, and UHDRS hand and forearm function items were not
changed by TBZ use. Improved TMT and 5TSST performance when on drug indicates that TBZ use may improve
balance and functional mobility in individuals with HD.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Chorea is a prominent and troublesome motor symptom of
Huntington's disease (HD). Frequent, large amplitude choreic move-
ments contribute to impairments in balance, walking, and daily activities,
such as getting up and down from a chair, andmay increase fall rates [1].
Symptomatic treatment of chorea has the potential to improve motor
function, safety, and quality of life. Tetrabenazine (TBZ) is a vesicular
monoamine transporter 2 (VMAT-2) inhibitor that causes a depletion of
monoamines, particularly dopamine, in the brain and has been used to
treat involuntary movements in a variety of movement disorders. Since
the FDA approved the use of TBZ speciﬁcally for treatment of chorea in
HDwith orphan drug status in 2007, the use of thismedication in individ-
uals with HD has increased in the United States. Though its effect on
dampening chorea is now well established, few studies of its effect on
other motor and functional parameters have been undertaken.
Several neuroleptics and TBZ have been shown to decrease chorea
but there are only limited studies of their effects on other motor3W. 10thAve., 516AtwellHall,
0; fax: +1 614 292 5922.
yer).
. This is an open access article underfunctions in HD. The administration of the neuroleptic haloperidol to in-
dividuals affected by HD reduced chorea but showed no effects on
spatial or temporal measures of gait [2,3]. Studies in a small number of
individuals with HD on high doses of some atypical neuroleptics
(i.e., olanzapine, zotepine) have documented improvements in
chorea as well as ﬁne motor tasks, oral functions, and some gait
measures [4,5]. Following administration of TBZ for 80 weeks in 75 indi-
vidualswithHD, improvements in chorea scores and in Global Improve-
ment rating without improvement in total motor and functional
measures from the Uniﬁed Huntington's Disease Rating Scale
(UHDRS) were reported [6]. Gait andmobility measures were not stud-
ied in detail. However, a study of 11 individuals with HD found an asso-
ciation between TBZ and improved lifting of large, light objects [7] and
another reported improvements in both chorea and functional mea-
sures of balance and gait (i.e., Berg Balance Scale, Dynamic Gait Index)
in 10 individuals on TBZ [8]. These observations suggest that there is a
need for more detailed investigations into the speciﬁc effects of TBZ ad-
ministration on upper extremity function, gait and functional mobility
in individuals with HD.
Previous studies evaluating TBZ in HD lacked assessment of a range
of balance measures, functional tasks and quantitative changes in gait
other than velocity. Therefore the purpose of this studywas to comparethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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TBZ in individuals with HD. It was hypothesized that the use of TBZ, ei-
ther by improving chorea or possibly by modulating other neurological
pathways, would improve 1) spatiotemporal gait parameters as mea-
sured by the GAITRite, 2) balance and/or mobility as measured by the
Tinetti Mobility Test (TMT), Five Times Sit-to-Stand Test (5TSST), and
Six Condition Romberg tests, and 3) function of the hand and forearm
as measured by ﬁnger tapping, hand pronation/supination, and Luria
(ﬁst-hand-palm) tests (items 6–8) on the UHDRS motor scale in indi-
viduals on stable doses of TBZ. Results of this prospective open-label
studywill contribute to our understanding of the impact of TBZ on func-
tional activities in the HD population.
2. Subjects and methods
Ambulatory individualswith a genetically conﬁrmeddiagnosis of HD,
who had been maintained on a stable dose of TBZ for at least 30 days,
were recruited for this study from The Ohio State University HDSA Cen-
ter of Excellence. Exclusion criteria included presence of another neuro-
logic disorder (i.e., CVA, TBI), presence of an orthopedic condition that
impeded the ability to walk, pregnancy, or inability to consent to the
study. Written informed consent, approved by the Institutional Review
Board, was obtained from all subjects prior to enrollment.
2.1. Procedures
Subjectswere instructed to stop TBZ on the daybefore testing and all
subjects were off TBZ for at least 18 h prior to undergoing study tests.
This ensured a period of at least 2 half-lives for metabolism of the active
metabolite, alpha-dihydrotetrabenazine. Subjects arrived at the Center
off-TBZ. After obtaining demographic information, the subjects were
tested on the following measures:
1. TheUHDRSmotor scalewas used to quantifymotor symptoms. Items
are rated on a 0–4 scale with higher scores indicating greater disabil-
ity. Total motor scores (range 0–124), total chorea scores (item 7,
range 0–28), and total forearm and hand function scores (items
6–8, range 0–12) [9] were calculated for each participant. The
UHDRS is a commonly used outcome measure for HD clinical trials
and has established reliability and validity [10].
2. Spatiotemporal parameters of walking (i.e., velocity, step and stride
length and duration, percent of gait cycle in stance, swing, and dou-
ble support, heel-to-heel base of support) were measured by a 16′
long GAITRite system (CIR Systems, Inc, Haverton, PA). GAITRite cal-
culates swing percent and double support percent for each leg rather
than across the entire cycle. Subjects began walking 2 m before and
stopped 2 m beyond the edges of the walkway to allow for accelera-
tion and deceleration phases. All subjects completed four separate
passes across the GAITRite walking at their comfortable self-
selected speed. The walks were averaged for analysis using the
GAITRite software program. GAITRite measures are reliable and
valid in individuals with HD [11].
3. The TMT is reliable and valid in individuals with HD and was used
to measure balance, functional mobility, and fall risk [12,13]. The
maximum possible score is 28 (balance subscale = 16, gait sub-
scale = 12), with higher scores indicating better performance.
4. The FTSST assessed the subjects' abilities to balance while standing
up and sitting down ﬁve times as quickly as possible from a standard
armless chair. The FTSST has been shown to be a reliable and valid
measure in older adults and other patient populations [14].
5. The Six Condition Romberg test was used to measure static balance.
Subjects were asked to stand with arms crossed over the chest and
hold each of the following stances and conditions for 30 s: 1) feet to-
gether, 2) feet together and eyes closed, 3) feet aligned in a tandem
heel-to-toe position, 4) tandem position and eyes closed, 5) tandem
position while counting backwards by 3's from 100, and 6) tandemposition while counting backwards by 3's from 100 with eyes closed
[15]. If the participant could not hold a stance for the full 30 s, the
Romberg test ended at that point.
After the initial testing, the subjects were instructed to take their
usual dose of TBZ. The same tests were then administered following a
2–3 hour resting period. Kenney et al. [16] documented that chorea
scores begin to improve within an hour of administration of TBZ, with
ameanduration of effect on chorea lasting 5.4±1.3 h [16]. Themajority
of subjects hadmaximal beneﬁt (physician rating) within 2 h of admin-
istration [16]. A neurologist with the European Huntington's Disease
Network UHDRS motor rater certiﬁcation administered the UHDRS
motor scale. All other tests were administered by one of three physical
therapist researchers who had considerable experience with test ad-
ministration. Each subject was evaluated by the same tester for off-
and on-TBZ tests. All subjects had practice trials of each test prior to
the recorded testing to ensure understanding and to eliminate learning
effects. During all gait and functional tests, subjects were guarded by
one of the investigators. Safetywas ensured during the off-TBZ time pe-
riod by asking a family member to drive them to the testing site and by
closemonitoring by the investigators or familymembers. Previous stud-
ies have shown no signiﬁcant adverse effects from the sudden with-
drawal of TBZ [16,17].
All statistical analyseswere performedusing SPSSVersion 21. All data
was examined for normality using the Shapiro–Wilk Test of Normality.
Accordingly, all analyses of gait and functional data were performed
using paired t-tests or the Wilcoxon matched-pairs signed-rank test. A
sample size of 13 participants was determined a priori to detect a change
of 0.5 m/s in gait velocity with 95% power. To examine the variability of
spatiotemporal measures of gait, coefﬁcient of variation (CV) values
were calculated for step time, stride length, swing time and double sup-
port time. Increased variability of gaitmeasures has been associatedwith
an increased fall risk in individuals with HD [1]. The alpha level for each
test was adjusted using a Bonferroni correction.
3. Results
A total of ﬁfteen individuals were recruited within a 2 year period;
four subjects were excluded due to a previously undocumented history
of amild CVA (n=1), an inability to participate in follow-up testing due
to family issues (n= 2), and an elected termination of the medication
(n = 1). Eleven ambulatory individuals with HD [mean age ± SD
(range) = 52.2 ± 10.0 (33–69 years); 9 women; mean time since
symptom onset = 8.1 ± 5.7 (2.5–21 years); mean CAG repeat size =
44.6 ± 1.6 (41–51)] completed the study. All subjects historically had
chorea scores N10 before starting on TBZ. The average daily dosage of
TBZ was 64.7 ± 20.8 mg with a range of 37.5 mg to 100 mg. All other
medications taken by subjects were stable during the month prior to
testing. In addition, none of the subjects or caregivers reported devia-
tion from their usual daily activities or initiation of any new exercise
regimen in the month preceding the testing.
Tetrabenazine use was associated with signiﬁcant improvements in
meanUHDRS total motor scores [off-TBZ= 55.27± 12.09 (32–78) and
on-TBZ = 47.73 ± 12.51 (27–69); p = .001] with the change in total
motor scores driven primarily by the increase in the chorea scores in
the off state [chorea scores off-TBZ = 17.09 ± 3.3 (13–25) and on-
TBZ = 12.91 ± 2.8 (10–19)]. However, total motor scores excluding
chorea measures of the face, trunk, upper extremity and lower extrem-
ity [off-TBZ = 38.18 ± 11.03 (19–61) and on-TBZ = 34.82 ± 11.50
(17–58)] were also still signiﬁcantly better (p= .008) on TBZ.
Spatiotemporal parameters of gait including CVs remained stable in
the on-TBZ and off-TBZ conditions (Table 1). Gait parameters of the left
and right leg were also compared and showed no signiﬁcant differences
side to side. Subjects exhibited signiﬁcantly better TMT total and bal-
ance subscale scores (p = .002; 10/11 participants' scores were im-
proved) and FTSST scores (p = .009; 9/11 participants had faster
Table 1
Comparison of gait parameters on and off tetrabenazine.
Outcome measures
(n = 11)
Mean ± SD t Sig.
(2-tailed)
Off On
Velocity (m/s) 1.23 ± 0.35 1.17 ± 0.27 0.76 0.464
Stride length (cm) 125.45 ± 27.65 124.24 ± 19.42 0.24 0.816
Swing percent of gait
cycle (%)
36.02 ± 2.82 36.53 ± 4.12 −0.72 0.488
Double support percent
of cycle (%)
27.98 ± 4.23 28.94 ± 4.23 −1.30 0.224
Stride length CV 6.87 ± 4.37 6.35 ± 2.95 0.61 0.557
Double support time CV 11.65 ± 6.70 11.70 ± 8.90 0.62Ζ 0.534
Ζ Z value; CV, coefﬁcient of variation; TBZ, tetrabenazine.
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niﬁcant changes in the Six Item Romberg total time. There was a trend
toward improved UHDRS forearm and hand function scores (items
6–8) (Table 2).
All individuals who participated in the study stated that they felt
“more stable” and “have better balance” while on TBZ. Additionally
some of the participants stated that they felt their hand function im-
proved while on TBZ. The study authors noted qualitatively that the in-
dividuals who respond well to TBZ appear to be more consistent stride
to stride during gait with less large amplitude trunk sway.
4. Discussion
Ourﬁndings contribute information to the growing body of evidence
from preliminary, non-randomized studies showing that TBZ may con-
tribute to improvements in balance and functional mobility in individ-
uals with a good response to TBZ [8]. We also showed that this small
group of TBZ responders did not exhibit parkinsonian gait changes.
This study conﬁrms previous work demonstrating a signiﬁcant im-
provement in UHDRS total motor and chorea scores on-TBZ than off-
TBZ [6,7].
4.1. Balance
The signiﬁcantly better total TMT score on-TBZ is explained primar-
ily by improvements in the balance subscale rather than the gait sub-
scale. The balance subscale includes observations of the individual
rising from and returning to a sitting position and turning 360°. Im-
provements in these activities on TBZ may have important clinical im-
plications since patients with HD commonly report falls while
standing up, sitting down and executing turns. In contrast, the six con-
dition Romberg test, a test of static standing balance under altered so-
matosensory conditions, was not signiﬁcantly improved in the on-TBZ
state. Taken together these ﬁndings suggest that TBZ has a greater im-
pact on balance control systems that maintain balance during dynamic
functional tasks (i.e., transfers, turning, walking) compared to those
that control balance during static tasks (i.e., standing with a narrowed
base of support or with altered vision) [18]. The improved TMT scores
found in our study support the ﬁndings of Fekete et al. [8] that TBZTable 2
Comparison of functional outcome measures on and off tetrabenazine.
Outcome measures (n = 11) Mean ± SD
Off
Tinetti Mobility Test (scores) 17.09 ± 4.0
Tinetti Mobility Test Balance Subscale (scores) 11.18 ± 2.0
Tinetti Mobility Test Gait Subscale (scores) 5.91 ± 2.4
Five Times Sit-to-Stand Test (s) 15.52 ± 3.8
Six Item Romberg Test (total time completed in s)* 73.26 ± 16
UHDRS forearm and hand function scores (items 6–8) (scores) 12.73 ± 4.0
Ζ = Z value; * = statistically signiﬁcant with Bonferroni correction; p ≤ .010.use improved performance on the Berg Balance Scale and the Dynamic
Gait Index in individuals with HD.
4.2. Gait
Spatiotemporal gait parameters and CVs measured on the GAITRite
did not change in the on-TBZ state compared to off-TBZ. Our ﬁndings
concur with those of Ferrara et al. [7] and Fekete et al. [8] who reported
no change in gait velocity on-TBZ versus off-TBZ. Walking in a straight
path does not place as high of demands on control of center of mass, es-
pecially in the medial-lateral direction as turning while walking, sit-to-
stand and sit to walk transitions [19] which may account for the lack of
effect of TBZ on spatiotemporal gait measures. Documented side effects
of TBZ include an increase in parkinsonian symptoms, such as bradyki-
nesia and rigidity [6] due to the dopamine depleting properties of TBZ.
We postulated that a parkinsonian gait disorder might be observed in
the on-TBZ state as suggested by decreased velocity or stride length.
However, this was not observed; TBZ did not have a parkinsonian im-
pact on spatiotemporal measures of gait or gait variability in any of
the participants. In fact, gait variability measures (CVs) were compara-
ble to ﬁndings in previous studies of TBZ naïve individuals with HD
[20] indicating that the use of TBZ did not increase gait variability and
its associated fall risk.
4.3. Hand and forearm function
Although there was not a signiﬁcant change in the UHDRS forearm
and hand function scores between on-TBZ and off-TBZ, improvement
in these measures warrants further investigation utilizingmore quanti-
tative measures such as the Nine Hole Peg Test [21] or Q-motor testing
[22]. TheUHDRSmotor scale has only three items examininghand func-
tion and uses an ordinal scale, with limited sensitivity to change. Our
work is in agreementwith Fekete et al. [8] who examined hand function
using the Jebsen Hand Function Test but did not ﬁnd any difference be-
tween the on-TBZ and off-TBZ states. The Jebsen test primarily exam-
ines manipulation of objects of different sizes and weights and may
not be sensitive to ﬁner motor changes. The Nine Hole Peg Test exam-
ines ﬁne motor control of the ﬁngers while the Q-motor test examines
isometric grip force measurements with a weighted object and ﬁnger
tapping speed, which may make these tests more sensitive measures
of potential effects of anti-choreic medication on upper extremity
function.
In the context of the current study, we are unable to determine
whether the improvements in motor function that we observed were
due solely to changes in severity of chorea or possibly to other neurolog-
ic effects of TBZ or perhaps to a combination of effects. The 4 point re-
duction (indicating improvement) in chorea scores in the on-TBZ
versus off-TBZ state was similar to the 5 point reduction reported by
Poon et al. [23] A signiﬁcant improvement in the total UHDRS motor
scores on-TBZ versus off-TBZ was observed, even when the chorea
scores were removed. The decrease noted in total UHDRS motor scores
excluding chorea scores appears to be related to combined improve-
ments in the hand and forearm function items and in the retropulsion
pull test, gait, and tandem walking items, as none of these items weret Sig. (2-tailed)
On
4 19.91 ± 3.53 4.20 .002*
8 13.09 ± 2.02 −4.61 .001*
3 6.82 ± 1.72 −1.84 .096
1 12.61 ± 3.00 3.20 .009*
.29 83.08 ± 27.57 1.58Ζ .114
3 11.36 ± 4.15 2.24 .049
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ly. The improvements in the pull test, gait, and tandem walking items
are most likely related to improved dynamic balance as supported by
our ﬁndings on the TMT and previous ﬁndings of Fekete et al. [8] on
the Dynamic Gait Index. However, Fekete et al. [8] did not note a signif-
icant change in the residual UHDRS score when the chorea scores were
removed. Differences in study designs, patient populations, other con-
comitant medications or patient age distributions between studies
may explain this dissimilarity in ﬁndings.
4.4. Limitations
Thiswas an exploratory studywith a small sample size selected from
one clinical site, limiting the extrapolation of these ﬁndings to a
larger and broader population. More robust differences between on-
and off-states may have been seen if we had not limited the time off-
drug to a relatively short time (slightly more than 18 hours), unlike
the 3–4 days participants were off-drug for the Fekete et al. study [8].
The primary reason for using a shorter time was to make the study
less of an imposition on the participants' regular routine. In addition,
Kenney et al. [16] have demonstrated that chorea scores begin to wors-
en on average around 5.4 ± 1.3 h after administration suggesting that
there should have been signiﬁcant wash out and concomitant decrease
in the effect of TBZ by 18 h. Despite the longer wash out period in the
Fekete et al. study [8], we still noted signiﬁcant differences in similar
study measures of dynamic balance.
Another limitation of this study is that the examiners and partici-
pants were not blinded and therefore the results could be biased. How-
ever, the majority of the outcome measures involved quantitative
assessments that are not easily biased. The TMT has a subjective compo-
nent that makes it more susceptible to bias, but the test has high test–
retest reliability [13] in the HD population and the researchers who ad-
ministered the test were highly experienced in using the tool and thus
less likely to make errors. The GAITRite is a useful tool for quantitative
assessment of gait; however, measures of gait variability are limited to
comparison across a mean of 60 steps due to the length of the GAITRite
and thus may be insufﬁcient to adequately analyze variability seen in
daily ambulation.
This study included only those individuals who did not experience
signiﬁcant side effects from TBZ, who had beenmaintained on themed-
ication successfully for over a month, and who reported and had con-
ﬁrmed improvement in their chorea scores prior to enrollment. TBZ
has been associated with a fairly wide range of potential side effects
and many individuals do not continue on the medication. Thus, this
study does not examine the impact of TBZ across all individuals with
Huntington's chorea. It would be clinically useful to identify disease fea-
tures that would predict individuals who are more likely to respond
well to TBZ. While several of our patients have reported less falls on
TBZ, some patients have reported deterioration in gait or increased
falls as reasons for stopping the medication. Older individuals are
reportedly more likely to develop parkinsonian features on TBZ [24].
Anecdotally, an increase in parkinsonian gait features including
festination and decreased stride length in two elderly male patients
with HD led to discontinuation of TBZ before reaching a stable dose. Fu-
ture studies should consider administering a detailed gait assessment
and a falls history prior to starting TBZ, allowing comparison of gait pa-
rameters, fall rates, and other contributing factors in those who choose
to continue versus stop TBZ.
4.5. Conclusions
The current study provides further conﬁrmation that TBZ improves
chorea and supports the hypothesis that TBZ improves functional mo-
bility by improving dynamic balance in individuals who beneﬁtted
from TBZ administration. Our study provides preliminary evidence sug-
gesting that TBZ does not negatively impact motor function in walkingand transfers and that individuals with improvement in chorea on TBZ
may also experience improvements in functional mobility such as turn-
ing and getting up anddown from a chair. Qualitative observations indi-
cate that future studies examining trunk movements and ﬁne motor
function of the hand on and off TBZ using more quantitative measures
may be indicated. Future attempts to identify which patients would
beneﬁt most from TBZ might include not only presence of chorea, but
also the degree of impairments in balance and gait.
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